Changeflow GovPing Pharma & Drug Safety OHSU Y-90 radioembolization with immunotherapy ...
Routine Notice Final

OHSU Y-90 radioembolization with immunotherapy liver cancer trial

Favicon for clinicaltrials.gov ClinicalTrials.gov
Detected April 6th, 2026
Email

Summary

National Library of Medicine registered a new clinical trial (NCT07511504) conducted by Oregon Health & Science University investigating Y-90 radioembolization combined with immunotherapy for liver cancer treatment. The trial is listed on ClinicalTrials.gov as a participant enrollment opportunity.

View original document View source feed page

What changed

Oregon Health & Science University registered a clinical trial on ClinicalTrials.gov (NCT07511504) studying the combination of Y-90 radioembolization with immunotherapy for liver cancer treatment. The trial details include eligibility criteria, study design, and enrollment information for prospective participants.

Healthcare providers and patients interested in liver cancer treatment options should review the trial details on ClinicalTrials.gov for enrollment eligibility. This is a routine registration entry with no compliance obligations for industry stakeholders.

Source document (simplified)

Show glossary

CFR references

42 CFR Part 11

Related changes

Favicon for clinicaltrials.gov TQD3524 Phase 1 trial targets carbapenem-resistant bacterial pneumonia
Routine Apr 06, 2026 • ClinicalTrials.gov • Pharma & Drug Safety
Favicon for clinicaltrials.gov First-in-human UX016 study for GNE Myopathy, Ultragenyx Pharmaceutical
Routine Apr 06, 2026 • ClinicalTrials.gov • Pharma & Drug Safety
Favicon for clinicaltrials.gov Clinical Trial Registration NCT07511621
Routine Apr 06, 2026 • ClinicalTrials.gov • Pharma & Drug Safety
Favicon for www.dir.ca.gov Adjustments to Official Medical Fee Schedule for Medicare DMEPOS Changes
Routine Apr 06, 2026 • CA DIR Labor News • Labor & Employment
Favicon for www.doj.state.or.us Medicaid Fraud Charges and Convictions - Multnomah County Cases
Priority review Apr 06, 2026 • AG: Oregon Media Releases • Courts & Legal
Favicon for grants.nih.gov Implementation of Changes for Basic Experimental Studies with Humans
Priority review Apr 06, 2026 • NIH Guide Funding Opportunities • Trade & Sanctions

Source

Favicon for clinicaltrials.gov
ClinicalTrials.gov clinicaltrials.gov/ct2/results/rss.xml
Pharma & Drug Safety
Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
NLM
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Docket
NCT07511504

Who this affects

Applies to
Healthcare providers Patients
Industry sector
6211 Healthcare Providers
Activity scope
Clinical Trial Registration
Geographic scope
United States US

Taxonomy

Primary area
Healthcare
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Pharmaceuticals Public Health

Browse Categories

Agriculture & Food Safety 63 AI Regulation 3 Banking & Finance 266 Consumer Protection 44 Courts & Legal 361 Data Privacy & Cybersecurity 74 Defense & National Security 52 Education 20 Energy 101 Environment 85 Environmental Permits 1 Environmental Regulation 13 Government & Legislation 278 Healthcare 136 Housing 16 Immigration 9 Insurance 58 Labor & Employment 113 Legislative 1 Pharma & Drug Safety 104 Public Health 3 Securities & Markets 104 Securities Regulation 15 Tax 66 Telecom & Technology 47 Trade & Sanctions 124 Transportation 57

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ClinicalTrials.gov publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.